REGN Relative Valuation
REGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, REGN is overvalued; if below, it's undervalued.
Historical Valuation
Regeneron Pharmaceuticals Inc (REGN) is now in the Fair zone, suggesting that its current forward PE ratio of 16.53 is considered Fairly compared with the five-year average of 16.52. The fair price of Regeneron Pharmaceuticals Inc (REGN) is between 458.20 to 689.52 according to relative valuation methord.
Relative Value
Fair Zone
458.20-689.52
Current Price：588.34
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.14
P/B
Median3y
3.45
Median5y
3.96
4.94
FCF Yield
Median3y
5.47
Median5y
5.42
Competitors Valuation Multiple
The average P/S ratio for REGN's competitors is 5.30, providing a benchmark for relative valuation. Regeneron Pharmaceuticals Inc Corp (REGN) exhibits a P/S ratio of 4.64, which is -12.36% above the industry average. Given its robust revenue growth of -3.70%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Regeneron Pharmaceuticals Inc (REGN) currently overvalued or undervalued?
What is Regeneron Pharmaceuticals Inc (REGN) fair value?
How does REGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Regeneron Pharmaceuticals Inc (REGN) as of May 24 2025?
What is the current FCF Yield for Regeneron Pharmaceuticals Inc (REGN) as of May 24 2025?
What is the current Forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN) as of May 24 2025?